Jeffrey Frelick
CEO & PresidentMr. Jeffrey Frelick, also known as Jeff, has been the President and Chief Executive Officer at Bone Biologics Corporation since June 28, 2019. He served as Chief Operating Officer at Bone Biologics, Corp. since August 17, 2015 until June 2019. He was the COO of Life Science Enterprises. Mr. Frelick served as a Managing Director of Life Sciences at Canaccord Genuity, Research Division. Mr. Frelick covered diagnostic devices and life science tools within the healthcare and life sciences sector for the United States region. Earlier, he was a Senior Analyst at Canaccord Genuity. He joined the Canaccord in September 2010. Mr. Frelick was a Senior Analyst at ThinkEquity LLC, Research Division and Lazard Capital Markets LLC, Research Division, where he was covering the diagnostic industry. He served as a Medical Device Associate Analyst at Susquehanna Financial Group, LLLP, Research Division, Leerink Swann LLC, Research Division(Leerink Partners LLC, Research Division) and RBS Research. Prior to Wall Street, Mr. Frelick was a Consultant at Boston Biomedical Consultants, from 1997 to 1999, where he provided strategic planning assistance, market research data and due diligence for diagnostic companies on a global basis. Between 1991 and 1997, he was a Sales Representative and Regional Sales Manager at Becton Dickinson and Company. Earlier, he worked as a Laboratory Technologist at Clinical Pathology Facility. Mr. Frelick earned a B.S. in Biology from the University of Pittsburgh and an M.B.A. from Suffolk University’s Sawyer Business School.
Positions
- Company NameBone Biologics CorporationStock CodeBBLGPositionCEO & President
